{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:18:01Z","timestamp":1774009081376,"version":"3.50.1"},"reference-count":95,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T00:00:00Z","timestamp":1580774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["GPP3"],"award-info":[{"award-number":["GPP3"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Single\u2010tablet regimens (STRs) of highly safe and effective combination antiretroviral therapy (cART) have had a significant beneficial impact on the clinical outcomes and lives of people living with HIV (PLHIV). As a consequence, healthcare professionals caring for PLHIV in high\u2010income countries have increasingly focused on issues beyond those related to HIV itself, i.e. HIV\u2010related neurological disease, or associated opportunistic infections, which include co\u2010infections, and primarily age\u2010 and lifestyle\u2010related comorbidities such as cardiovascular disease, diabetes mellitus, renal impairment, osteoporosis and frailty. This review considers drug side effects and comorbidities seen in PLHIV and evaluates the role of a recently licensed STR \u2013 bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) \u2013 in mitigating some of those challenges. Factors that need to be evaluated for initial cART regimens include: pretreatment CD4 cell count; plasma HIV RNA; HIV drug resistance; hepatitis B co\u2010infection; HLA\u2010B*5701 status; drug\u2010drug interactions; pregnancy and pregnancy potential; psychiatric and physical comorbidities such as renal or bone disease, as well as simplicity and adherence\u2010friendliness, all of which need to be considered in all lines of therapy. BIC\/FTC\/TAF constitutes a new STR that includes an unboosted integrase strand transfer inhibitor with a high barrier against resistance with TAF and FTC. Its virological efficacy was non\u2010inferior to dolutegravir\u2010based regimens previously recommended by most guidelines for treatment initiation in large double\u2010blind, randomised clinical trials in treatment\u2010na\u00efve or switch patients over 96\u00a0weeks. Tolerability and pharmacological properties of the regimen make it a useful tool to address several of the clinical management issues raised above.<\/jats:p>","DOI":"10.1111\/hiv.12833","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T09:19:45Z","timestamp":1580807985000},"page":"3-16","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The potential role of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) single\u2010tablet regimen in the expanding spectrum of fixed\u2010dose combination therapy for HIV"],"prefix":"10.1111","volume":"21","author":[{"given":"H\u2010J","family":"Stellbrink","sequence":"first","affiliation":[{"name":"ICH Study Center Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lazzarin","sequence":"additional","affiliation":[{"name":"San Raffaele Scientific Institute Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2928-1291","authenticated-orcid":false,"given":"I","family":"Woolley","sequence":"additional","affiliation":[{"name":"Monash Medical Centre Monash University Melbourne Vic Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JM","family":"Llibre","sequence":"additional","affiliation":[{"name":"University Hospital Germans Trias i Pujol and the \u201cFight AIDS\u201d Foundation Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,4]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30086-3"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30066-8"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.11606\/S1518-8787.2018052000399"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.844685"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu701"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_2_16_10_1","unstructured":"van WykJ AjanaF BisshopFet al.Switching to DTG\/3TC fixed\u2010dose combination (FDC) is non\u2010inferior to continuing a TAF\u2010based regimen in maintaining virologic suppression through 48 weeks (TANGO study). 10TH IAS Conference on HIV Science Mexico 21\u201024 July 2019. #WEAB0403LB."},{"key":"e_1_2_16_11_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available atwww.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf(accessed January 2020)."},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835f1db0"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001350"},{"key":"e_1_2_16_14_1","unstructured":"GatellJM AssoumouL MoyleGet al.Cardiovascular risk in HIV patients switching from a boosted protease inhibitor (PI) to dolutegravir (DTG). IAS 2017. Abstract TUAB0102. ClinicalTrials.gov NCT02098837."},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00012"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30043-2"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/2047487315579291"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328351f68f"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0293"},{"key":"e_1_2_16_20_1","volume-title":"BHIVA Guidelines for the Treatment of HIV\u20101\u2010Positive Adults with Antiretroviral Therapy 2015 (2016 Interim Update)","author":"British HIV Association (BHIVA)","year":"2016"},{"key":"e_1_2_16_21_1","unstructured":"WHO.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach \u2010 Second edition. June 2016. Available athttps:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/(accessed 4 September 2019)."},{"key":"e_1_2_16_22_1","unstructured":"National Institute for Health and Care Excellence. BNF. Available athttps:\/\/bnf.nice.org.uk(accessed 4 September 2019)."},{"key":"e_1_2_16_23_1","unstructured":"RathbunRC.Antiretroviral therapy for HIV infection. Available athttps:\/\/emedicine.medscape.com\/article\/1533218-overview#a1(accessed 4 September 2019)."},{"key":"e_1_2_16_24_1","doi-asserted-by":"crossref","unstructured":"CahnP Sierra MaderoJ ArribasJet al.Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment\u2010naive adults with HIV\u20101 infection \u2010 96\u2010week results from the GEMINI studies. 10th International AIDS Conference on HIV Science (IAS 2019) 21\u201324 July 2019 Mexico City Mexico.","DOI":"10.1097\/QAI.0000000000002394"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12716"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8431"},{"key":"e_1_2_16_27_1","unstructured":"European Aids Clinical Society (EACS).Guidelines. Version 10.0 November 2019. Brussels Belgium: EACS 2019.www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html(accessed January 2020)."},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_16_29_1","unstructured":"PodzamczerD StellbrinkH OrkinCet al.B\/F\/TAF versus ABC\/DTG\/3TC or DTG+F\/TAF in treatment\u2010naive adults with high baseline viral load or low base\u2010line CD4 count in two Phase III randomized controlled clinical trials: Week 96 results. HIV Glasgow P119; 28\u201331 October 2018 Glasgow UK."},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_16_31_1","unstructured":"OrkinC SaxPE ArribasJet al.Long\u2010term efficacy and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in ART\u2010na\u00efve adults. Presented at 17th European AIDS Conference November 6\u20139 2019 Basel Switzerland. Abstract PE3\/14."},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1807653"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905230"},{"key":"e_1_2_16_34_1","unstructured":"ZashR HolmesL DisekoMet al.Neural tube defects by antiretroviral and HIV exposure in the Tsepamo Study Botswana. 22ND IAS International AIDS Conference Mexico July 2019. Abstract MOAX0105LB."},{"key":"e_1_2_16_35_1","unstructured":"WHO.Update of recommendations on first\u2010 and second\u2010line antiretroviral regimens. Policy brief. July2019. Available at:https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325892\/WHO-CDS-HIV-19.15-eng.pdf(accessed 4 September 2019)."},{"key":"e_1_2_16_36_1","unstructured":"PereiraG KimA JalilEet al.No occurrences of neural tube defects among 382 women on dolutegravir at pregnancy conception in Brazil. 10th IAS Conference on HIV Science Mexico City. Abstract MOAX0104LB 2019."},{"key":"e_1_2_16_37_1","volume-title":"British HIV Association Guidelines for the Management of HIV Infection in Pregnant Women 2018 (consultation draft)","author":"British HIV Association (BHIVA)","year":"2018"},{"key":"e_1_2_16_38_1","unstructured":"European Medicines Agency. Press Release. Available at:www.ema.europa.eu\/en\/news\/new-study-suggests-risk-birth-defects-babies-born-women-hiv-medicine-dolutegravir(accessed November 2018)."},{"key":"e_1_2_16_39_1","volume-title":"Updated recommendations on first\u2010line and second\u2010line antiretroviral regimens and post\u2010exposure prophylaxis and recommendations on early infant diagnosis of HIV. HIV treatment \u2013 interim guidance","author":"World Health Organization (WHO)","year":"2018"},{"key":"e_1_2_16_40_1","unstructured":"Gilead Sciences Ltd.Biktarvy 50 mg\/200 mg\/25 mg film\u2010coated tablets.www.medicines.org.uk\/emc\/product\/9313\/smpc(accessed September 2018)."},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.18000006"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"e_1_2_16_43_1","unstructured":"WhiteK Niedziela\u2010majkaA NovikovNet al.Bictegravir Dissociation Half\u2010life from HIV\u20101 G140S \/ Q148H Integrase\u2010DNA Complexes. Conference on Retroviruses and Opportunistic Infections (CROI) February 13\u201016 2017 Seattle WA #497."},{"key":"e_1_2_16_44_1","first-page":"PE357\u2013E365","article-title":"Switching to fixed\u2010dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV\u2010 1: 48 week results of a randomised, double\u2010blind, multicentre, active\u2010controlled, phase 3, non\u2010inferiority trial","volume":"5","author":"Molina J\u2010M","year":"2018","journal-title":"Lancet HIV"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_16_46_1","unstructured":"KityoC HaginsD KoenigEet al.Switching to bictegravir\/emtracitabine\/tenofovir alafenimide (B\/F\/TAF) in women. Available at:www.croiconference.org\/sessions\/switching-bictegraviremtracitabinetenofovir-alafenimide-bftaf-women(accessed September 2018)."},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0440-y"},{"key":"e_1_2_16_48_1","unstructured":"AIDSinfo.Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at:https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv\/0(accessed 4 September 2019)."},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy051"},{"key":"e_1_2_16_50_1","unstructured":"KinneyRG SpachDH.National HIV curriculum: adverse effects of antiretroviral medications. Available at:www.hiv.uw.edu\/go\/antiretroviral-therapy\/adverse-effects\/core-concept\/all(accessed September 2017)."},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12710"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001459"},{"key":"e_1_2_16_54_1","first-page":"A187","article-title":"5PSQ\u2010050 Neuropsychiatric adverse effects on dolutegravir: experience in a third\u2010level hospital","volume":"25","author":"Lopez TV","year":"2018","journal-title":"Eur J Hosp Pharm"},{"key":"e_1_2_16_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0322-8"},{"key":"e_1_2_16_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2626-z"},{"key":"e_1_2_16_57_1","unstructured":"RijndersB StephanC LazzarinAet al.Switching from ritonavir or cobicistat boosted atazanavir plus emtricitabine\/tenofovir disoproxil fumarate to a tenofovir alafenamide\u2010based single tablet regimen: week 48 data in virologically suppressed adults. 15th European AIDS Conference October 21\u201024 2015 Barcelona. Abstract PS10\/3."},{"key":"e_1_2_16_58_1","unstructured":"WinstonA PostFA DeJesusEet al.Phase 3 randomized controlled trial of switching to emtricitabine\/tenofovir alafenamide (F\/TAF) from abacavir\/lamivudine (ABC\/3TC) in virologically suppressed adults: week 48 results. 16th European AIDS Conference. October 25\u201027 2017. Milan. Abstract PS8\/4. Available at: www.natap.org\/2017\/EACS\/EACS_64.htm (accessed September 2018)."},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.2.191"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832cbcc2"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23375-6"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.083"},{"key":"e_1_2_16_63_1","doi-asserted-by":"publisher","DOI":"10.1086\/649897"},{"key":"e_1_2_16_64_1","first-page":"1100","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV","volume":"138","author":"Shah ASV","year":"2018","journal-title":"Syst Rev Meta\u2010Anal Circul"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1086\/656417"},{"key":"e_1_2_16_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2016.1243363"},{"key":"e_1_2_16_67_1","unstructured":"HoyJF.Effects of immediate versus deferred initiation of antiretroviral therapy on bone mineral density: a substudy of the INSIGHT strategic timing of antiretroviral therapy (START) Study. EACS 2015. Abstract ADRLH\u201062."},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001344"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000089"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00348-5"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000273"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2016.08.117"},{"key":"e_1_2_16_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001525"},{"key":"e_1_2_16_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001504"},{"key":"e_1_2_16_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002844"},{"key":"e_1_2_16_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_16_77_1","unstructured":"Aurobindo Pharma \u2013 Milpharm Ltd.Tenofovir disoproxil 245mg film\u2010coated tablets. SmPC.www.medicines.org.uk\/emc\/product\/9370\/smpc(accessed September 2018)."},{"key":"e_1_2_16_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001186"},{"key":"e_1_2_16_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-016-0315-y"},{"key":"e_1_2_16_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_16_81_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2009.009126"},{"key":"e_1_2_16_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000180"},{"key":"e_1_2_16_83_1","unstructured":"De CastroN MarcyO ChazallonCet al.Virologic efficacy of raltegravir vs. efavirenz\u2010based antiretroviral treatment in HIV1\u2010infected adults with tuberculosis: W48 results of the ANRS 12300 REFLATE TB2 trial. 10th IAS Conference on HIV Science (IAS 2019) July 21\u201024 2019 Mexico City. Abstract MOAB0101."},{"key":"e_1_2_16_84_1","unstructured":"CROI 2017 # 731 (ATHENA)www.croiconference.org\/sessions\/integrase-inhibitors-are-independent-risk-factor-iris-athena-cohort-study(accessed September 2018)."},{"key":"e_1_2_16_85_1","unstructured":"CROI 2017 # 732 (Dat\u2019AIDS Study Group)www.croiconference.org\/sessions\/initiation-art-based-integrase-inhibitors-increases-risk-iris(accessed September 2018)."},{"key":"e_1_2_16_86_1","unstructured":"REALITY CROI2018www.croiconference.org\/sessions\/impact-raltegravir-intensification-first-line-art-iris-reality-trial(accessed September 2018)."},{"key":"e_1_2_16_87_1","unstructured":"OPTIMAL (CROI 2018 #495)www.croiconference.org\/sessions\/are-integrase-inhibitors-risk-factor-iris-anrs-146-optimal-trial(accessed September 2018)."},{"key":"e_1_2_16_88_1","unstructured":"INSPIRING (CROI 2018)http:\/\/www.croiconference.org\/sessions\/safety-and-efficacy-dolutegravir-based-art-tbhiv-coinfected-adults-week-24(accessed September 2018)."},{"key":"e_1_2_16_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1082"},{"key":"e_1_2_16_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1082"},{"key":"e_1_2_16_91_1","unstructured":"ViiV Healthcare UK Ltd.Tivicay film\u2010coated tablets SmPC.www.medicines.org.uk\/emc\/product\/5248\/smpc(accessed September 2018)."},{"key":"e_1_2_16_92_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.14.21"},{"key":"e_1_2_16_93_1","unstructured":"HIV InSite.Database of antiretroviral drug interactions. Available at:http:\/\/hivinsite.ucsf.edu\/insite?page=ar-00-02&post=10&param=8(accessed 5 September 2019)."},{"key":"e_1_2_16_94_1","unstructured":"Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM).Australian Commentary on the US Department of Health and Human Services (DHHS) Guidelines for the use of Antiretroviral Agents in HIV\u20101\u2010Infected Adults and Adolescents. Available at:http:\/\/arv.ashm.org.au\/arv-guidelines\/drug-interactions\/drug-drug-interactions#Table17(accessed September 2018)."},{"key":"e_1_2_16_95_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141164"},{"key":"e_1_2_16_96_1","doi-asserted-by":"publisher","DOI":"10.1086\/507894"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.12833","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:35:36Z","timestamp":1694133336000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,4]]},"references-count":95,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/hiv.12833"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12833","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,4]]},"assertion":[{"value":"2019-11-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}